U.S. Markets open in 1 hr 48 mins

GlaxoSmithKline plc (GSK.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
1,463.50+9.50 (+0.65%)
As of 12:18PM BST. Market open.
Full screen
Previous Close1,454.00
Bid1,463.00 x 175400
Ask1,463.50 x 417900
Day's Range1,455.50 - 1,465.50
52 Week Range1,444.00 - 1,745.56
Avg. Volume7,021,942
Market Cap71.06B
PE Ratio (TTM)37.43
Earnings DateN/A
Dividend & Yield1.01 (5.14%)
Ex-Dividend Date2017-08-10
1y Target EstN/A
  • Is GlaxoSmithKline plc (GSK) a Suitable Value Stock?
    Zacks22 hours ago

    Is GlaxoSmithKline plc (GSK) a Suitable Value Stock?

    GlaxoSmithKline is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.

  • Reutersyesterday

    GSK's new triple lung drug beats other modern inhalers in study

    GlaxoSmithKline produced clinical data on Wednesday showing its newly approved three-in-one inhaler reduced life-threatening attacks in chronic obstructive pulmonary disease (COPD) patients more than other modern treatments. Britain's biggest drugmaker believes the results confirm the potential of the once-daily single inhaler, Trelegy Ellipta, a product it hopes will offset the impact of generic competition to the older lung drug Advair. Trelegy won approval based on clinical tests showing it improved lung function and exacerbations more than AstraZeneca's long-established two-drug inhaler Symbicort, which works in a similar way to Advair.

  • FDA OKs Glaxo's inhaler, first one to combine 3 medicines
    Associated Press2 days ago

    FDA OKs Glaxo's inhaler, first one to combine 3 medicines

    TRENTON, N.J. (AP) — The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis.